New trial data and updated clinical guidance signal a shift toward precision care

Today’s IBD News Highlights

The field of Inflammatory Bowel Disease (IBD) research has seen significant advancements, with a focus on refining existing treatment strategies and better understanding the impact of the condition on patients’ lives. Recent clinical data presented at major conferences highlights the safety and durability of switching between anti-TNF drugs for children and young people who have stopped responding to their initial biologic therapy. New UK healthcare standards emphasize coordinated care and timely diagnosis, aiming to bridge the gaps between current practice and optimal patient management. Additionally, a comprehensive review of patient data reveals that nearly one-third of IBD patients experience moderate-to-severe disability, underscoring the need for clinicians to look beyond inflammation markers alone. These updates signify a shift towards precision care, with a focus on individualized treatment choices and a better understanding of the condition’s impact on patients’ quality of life.

Multiple Anti-TNF Switches Durable, Safe in Paediatric IBD

A study has shown that switching children and adolescents with IBD to a different anti-TNF drug after initial treatment failure appears safe and does not reduce the long-term effectiveness of the overall treatment plan. The analysis revealed that multiple intramolecular switches did not result in a significant drop in the long-term durability of the therapy, and the rate of adverse events remained stable and acceptable. This finding provides reassurance for paediatric gastroenterologists, confirming that cycling through advanced anti-TNF therapies is a sustainable strategy to maintain disease control in young IBD patients without increasing safety concerns.

(Source: https://www.medscape.com/)

The 2026 IBD UK Standards of Healthcare Service Design and Delivery

The IBD UK Standards have been updated for 2026, creating an aspirational framework for delivering high-quality care for individuals with Crohn’s disease and ulcerative colitis across the United Kingdom. The 60 resulting standards emphasize seven domains of care, including timely diagnosis, personalized care plans, improved flare management protocols, and better surgical outcomes. The new guidelines stress the need for all patients to have a named specialist responsible for their care and the importance of age-appropriate transition pathways from pediatric to adult services. These standards serve as a crucial benchmark for auditing service quality, helping patients and advocates push for improved, consistent healthcare delivery nationwide.

(Source: https://bmjopengastro.bmj.com/)

One-Third With Inflammatory Bowel Disease Have Moderate-to-Severe Disability

A systematic review has found that nearly 30% of IBD patients experience moderate-to-severe disability, with rates spiking to 57% during active disease, highlighting the chronic impact beyond inflammation. The research revealed that one in three people with Crohn’s disease or ulcerative colitis reports moderate-to-severe limitations in daily activities, work, and social functioning. Notably, disability persists in a considerable proportion of patients even when the disease is medically considered “in remission.” The findings highlight the critical need for clinicians to systematically assess patient-reported limitations, fatigue, and pain, rather than relying solely on blood tests or endoscopy results to define disease severity and guide long-term management strategies.

(Source: https://www.webmd.com/)

Pendulum Bets on Prebiotics with Gut Fuel as GLP-1 Buzz Reshapes Market

The nutritional supplement industry is shifting focus towards prebiotics and the microbiome, especially with the rise of GLP-1 weight loss drugs, seeking synergistic effects that impact gut health and metabolism. Supplement manufacturers are heavily investing in prebiotics, non-digestible fibers that feed beneficial gut bacteria, as the market reacts to the increasing use of GLP-1 agonist weight loss medications. For the IBD community, this highlights the ongoing research trend that focuses on the gut microbiome as a therapeutic target. While specific IBD patients often require caution with fiber intake, the wider industry focus validates the role of diet and microbial balance in chronic inflammatory conditions.

(Source: https://www.nutraingredients.com/)

Dual-Targeting Co-Antibody Therapy Shows High Efficacy in Refractory IBD

Phase 2b trial data has shown that a new dual-targeted co-antibody, JNJ-4804, achieved high remission rates in Crohn’s disease and ulcerative colitis patients who failed prior therapies. The DUET-UC and DUET-CD Phase 2b trials focused on patients with moderate-to-severe IBD who had already failed one or more systemic treatments, representing a challenging, refractory population. Results showed that the co-antibody achieved significantly higher rates of clinical remission and endoscopic response compared to existing anti-TNF monotherapies. The safety profile was comparable to using either monotherapy alone, suggesting a major potential advancement in achieving deeper, more sustained remission for those with limited remaining options.

(Source: https://www.verywellhealth.com/)